首页> 美国卫生研究院文献>Advanced Science >Drug‐Free Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel
【2h】

Drug‐Free Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel

机译:无毒在透明质酸水凝胶的四个月后的眼内压力的非药物减少4个月

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Glaucoma is the leading cause of irreversible blindness. Current treatments use drugs or surgery to reduce intraocular pressure (IOP). In this study, a drug‐free, nonsurgical method is developed that lowers IOP for 4 months without requiring daily patient adherence. The approach involves expanding the suprachoroidal space (SCS) of the eye with an in situ‐forming hydrogel injected using a microneedle. This study tests the hypothesis that SCS expansion increases the drainage of aqueous humor from the eye via the unconventional pathway, which thereby lowers IOP. SCS injection of a commercial hyaluronic acid (HA) hydrogel reduces the IOP of normotensive rabbits for more than 1 month and an optimized HA hydrogel formulation enables IOP reduction for 4 months. Safety assessment by clinical ophthalmic examinations indicate the treatment is well tolerated. Histopathology shows minor hemorrhage and fibrosis at the site of injection. Further analysis by ultrasound biomicroscopy demonstrates a strong correlation of IOP reduction with SCS expansion. Outflow facility measurements show no difference in pressure‐dependent outflow by the conventional pathway between treated and untreated eyes, supporting the hypothesis. In conclusion, SCS expansion with an in situ‐forming hydrogel can enable extended IOP reduction for treating ocular hypertension and glaucoma without drugs or surgery.
机译:青光眼是不可逆转的失明的主要原因。目前的治疗使用药物或手术以减少眼压(IOP)。在这项研究中,开发了一种无毒的非诊断方法,从而降低IOP 4个月而不需要日常患者依从性。该方法涉及使用微针注入的in原位形成水凝胶,将眼睛的Suprachoroidalsal(SCs)扩展。本研究试验SCS扩张通过非传统途径增加了SCS扩张从眼睛的幽默排水,从而降低了IOP。 SCS注射商业透明质酸(HA)水凝胶减少了1个多个月的正常兔IOP,优化的HA水凝胶配方能够降低4个月。临床眼科检查的安全评估表明治疗是良好的耐受性。组织病理学在注射部位显示出微小的出血和纤维化。通过超声生物显微镜的进一步分析表明IOP降低与SCS膨胀的强烈相关性。流出设施测量显示在处理和未经处理的眼睛之间的常规通路的压力依赖流出的差异没有差异,支持假设。总之,使用in原位形成水凝胶的SCS膨胀可以扩展IOP,用于治疗眼性高血压和无毒品或手术的青光眼。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号